ALDH1A1 and breast cancer: However, the high expression of putative CSC markers is consistently associated with poorer overall survival in BC patients (88), and the presence of residual ALDH1+ cells after neoadjuvant therapy is associated with increased metastasization risk (89), indicating that targeting CSCs would have a beneficial impact on patient life expectancy.